Additionally, a study is ongoing to explore the effects of the combination of divarasib plus cetuximab with or without chemotherapy (FOLFOX: 5-FU, leucovorin and oxaliplatin; or FOLFIRI: leucovorin, 5-FU and irinotecan; ClinicalTrials.gov: NCT04929223) in patients with KRAS G12C-positive CRC. Here, KRAS is linked to colorectal carcinoma.